期刊文献+

胎儿静脉导管血流频谱与染色体异常及心血管畸形的关系 被引量:13

原文传递
导出
摘要 目的探讨孕11~13^+6周胎儿静脉导管血流频谱波形与胎儿染色体异常及心血管畸形的关系。方法收集2009年7月至2012年12月在北京大学第一医院进行孕期保健并住院分娩的单胎孕妇6789名,无妊娠合并症及其他慢性病史。正常胎儿静脉导管频谱为“两峰一谷”的全心动周期正向血流(S-D-a),当出现a波消失或者反向时为异常,反复测量3次以排除假阳性。孕11~13^+6周的胎儿静脉导管出现a波消失或者反向时随访至孕中期行胎儿系统超声检查观察有无畸形,合并有其它畸形者结合临床,进行介入性产前诊断或继续随访,无畸形者继续随访至分娩后3天。结果6789名孕妇中胎儿静脉导管共有915例a波消失或者反向者作为研究组,其中发现染色体异常6例(0.66%),心血管畸形11例(1.20%);5874例a波正常者为对照组,其中染色体异常11例(0.19%),心血管畸形66例(1.12%)。研究组中发现简单型心血管畸形7例(0.77%),复杂型心血管畸形4例(0.44%);对照组中简单型心血管畸形61例(1.04%),复杂型心血管畸形5例(0.09%)。胎儿染色体异常和胎儿复杂型心血管畸形发生率在两组间差异有统计学意义(P=0.019,P=0.024),而简单型心血管畸形的发生率在两组间差异无统计学意义(P=0.445)。结论孕11~13怕周静脉导管血流频谱异常提示胎儿染色体异常和复杂心血管畸形的概率增加,a波消失或反向作为胎儿畸形筛查的超声指标应该给予重视,对于早期发现a波异常的胎儿,应该在孕中期进行详细的系统超声和超声心动图检查,并结合具体临床情况做出合理的处置。
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2015年第6期896-898,共3页 Chinese Journal of Medical Genetics
基金 国家“十一五”科技支撑计划(2006BA105A04)
  • 相关文献

参考文献19

  • 1Timmerman E, Clur SA, Pajkrt E, et al. First-trimester measurement of the ductus venosus pulsatility index and the prediction of congenital heart defects [J]. Ultrasound Obstet Gynecol, 2010, 36(6): 668-675.
  • 2Toyama JM, Brizot ML, Liao AW, et al. Ductus venosus blood flow assessment at 11 to 14 weeks of gestation and fetal outcome [J]. Ultrasound Obstet Gynecol, 2004, 23(4) :341-345.
  • 3Papatheodorou SI, Evangelou E, Makrydimas G, et al. First- trimester ductus venosus screening for cardiac defects: a meta- analysis[J]. BJOG, 2011, 118(12):1438-1445.
  • 4Martinez JM, Comas M, Borrell A, et al. Abnormal first- trimester ductus venosus blood flow: a marker of cardiac defects in fetuses with normal karyotype and nuchal translucency[J]. Ultrasound Obstet Gynecol, 2010, 35(3):267-272.
  • 5Bilardo CM, Mailer MA, Zikulnig L, et al. Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities : relationship with nuchal translucencymeasurement and fetal outcome[J]. Ultrasound Obstet Gynecol, 2001, 17(4) ..288-294.
  • 6Grande M, Arigita M, Borobio V, et al. First-trimester detection of structural abnormalities and the role of aneuploidy markers[J]. Ultrasound Obstet Gynecol, 2012, 39(2) : 157-163.
  • 7Jouannic JM, Thieulin AC, Bonnet D, et al. Measurement of nuchal translucency for prenatal screening of congenital heart defects: a population-based evaluation[J]. Prenat Diagn, 2011, 31(13) 1264-1269.
  • 8Chelemen T, Syngelaki A, Maiz N, et al. Contribution of ductus venosus Doppler in first-trimester screening for major cardiac defects[J]. Fetal Diagn Ther, 2011, 29(2):127-134.
  • 9Maiz N, Kagan KO, Milovanovic Z, et al. Learning curve for Doppler assessment of ductus venosus flow at 11 0 to 13 q- 6 weeks' gestation[J]. Ultrasound Obstet Gynecol, 2008, 31(5) : 503-506.
  • 10Maiz N, Nicolaides KH. Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications[J]. Fetal Diagn Ther, 2010, 28(2) :65-71.

二级参考文献10

  • 1Cerrilto HM, Yerena de Vega MC, Gonzalez Panzzi ME, et al. Genetic amniocentesis in high-risk populations. Experience in 308i cases[J]. Ginecol Obstet Mex, 2009, 77: 173-182.
  • 2Benacerraf BR. The role of the second trimester genetic sonogram in screening for fetal Down syndrome[J]. Semin Perinatol, 2005, 29: 386-394.
  • 3Tutschek B, Tercanli S. Current aspects of obstetric ultrasound in the screening setting[J]. Praxis, 2012, 101: 1473-1480.
  • 4Chuchracki M, Janiak J, Zi61kowska K, et al. Edwards syndrome-most frequent indications for genetic amnioeentesis. Analysis of the last 5 years[J]. Przeg Lek, 2012, 69: 1007- 1010.
  • 5Karadzov-Orlie N, Egic A, Milovanovic Z, et al. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome[J]. Prenat Diagn, 2012, 32: 638-643.
  • 6Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuehal translucency thickness, free beta- human chorionic gonadotropin and pregnancy-associated plasma protein-A[J]. Ultrasound Obstet Gynecol, 2008, 31: 618-624.
  • 7Saltvedt S, Almstrom H, Kublickas M, et al. Screening for Down syndrome based on maternal age or fetal nuchal translucency: a randomized controlled trial in 39,572 pregnancies [J]. Ultrasound Obstet Gynecol, 2005, 25: 537-545.
  • 8Sonek JD, Cicero S, Neiger R, et al. Nasal bone assessment in prenatal screening for trisomy 21 [J]. Am J Obstet Gynecol, 2006, 195: 1219-1230.
  • 9Falcon O, Faiola S, Huggon I, et al. Fetal tricuspid regurgitation at the i I -k 0 to 13 - 6-week scan., association with chromosomal defects and reproducibility of the method[J]. Ultrasound Obstet Gynecol, 2006, 27: 609-612.
  • 10Borenstein M, Minekawa R, Zidere V, et al. Aberrant right subclavian artery at 16 to 23+6 weeks of gestation a marker for chromosomal abnormality[J]. Ultrasound Obstet Gynecol, 2010, 36: 548-552.

同被引文献90

引证文献13

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部